Limits...
HtrA1: Its future potential as a novel biomarker for cancer.

Altobelli E, Marzioni D, Lattanzi A, Angeletti PM - Oncol. Rep. (2015)

Bottom Line: Most articles described in vivo studies using a morphological approach and immunohistochemistry, whereas protein expression was quantified as staining intensity scored by two raters.Often the results were not comparable due to the different rating scales and study design.Current research on HtrA1 does not conclusively support its role as a tumor suppressor.

View Article: PubMed Central - PubMed

Affiliation: Department of Life, Health and Environmental Sciences, Epidemiology and Biostatistics Unit, AUSL Teramo, University of L'Aquila, L'Aquila, Italy.

ABSTRACT
HtrA1 appears to be involved in several physiological processes as well as in the pathogenesis of conditions such as Alzheimer's disease and osteoarthritis. It has also been hypothesized to play a role as a tumor suppressor. This manuscript reviews the current cancer-related HtrA1 research from the methodological and clinical standpoints including studies regarding its potential role as a tumor marker and/or prognostic factor. PRISMA method was used for study selection. The articles thus collected were examined and selected by two independent reviewers; any disagreement was resolved by a methodologist. A laboratory researcher reviewed the methods and laboratory techniques. Fifteen studies met the inclusion criteria and concerned the following cancer sites: the nervous system, bladder, breast, esophagus, stomach, liver, endometrium, thyroid, ovaries, pleura, lung and skin. Most articles described in vivo studies using a morphological approach and immunohistochemistry, whereas protein expression was quantified as staining intensity scored by two raters. Often the results were not comparable due to the different rating scales and study design. Current research on HtrA1 does not conclusively support its role as a tumor suppressor.

No MeSH data available.


Related in: MedlinePlus

Flow-chart of the search strategy: HtrA1 and cancer.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4487665&req=5

f1-or-34-02-0555: Flow-chart of the search strategy: HtrA1 and cancer.

Mentions: The database search conducted as described above retrieved 43 studies, and the manual search retrieved 4 additional studies. No duplicates were found (Fig. 1). Examination of the abstracts led to the exclusion of 26 studies; 1 regarded rheumatoid arthritis (15); 3 studied macular degeneration (16–18); 2 investigated the placenta (7,19); 1 addressed tuberous sclerosis complex 2 (20); 3 were animal studies (21–23); 1 assessed amyloid precursor protein (4); 2 evaluated other biomarkers (24,25); 6 were exclusively in vitro studies (1;26–30); and 7 were reviews (2,31–36), thus leaving 21 studies. Examination of their full text led to the exclusion of 6 further studies since they did not report clinical studies (13,37–41). Overall, 15 studies met the inclusion criteria and are reviewed below.


HtrA1: Its future potential as a novel biomarker for cancer.

Altobelli E, Marzioni D, Lattanzi A, Angeletti PM - Oncol. Rep. (2015)

Flow-chart of the search strategy: HtrA1 and cancer.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4487665&req=5

f1-or-34-02-0555: Flow-chart of the search strategy: HtrA1 and cancer.
Mentions: The database search conducted as described above retrieved 43 studies, and the manual search retrieved 4 additional studies. No duplicates were found (Fig. 1). Examination of the abstracts led to the exclusion of 26 studies; 1 regarded rheumatoid arthritis (15); 3 studied macular degeneration (16–18); 2 investigated the placenta (7,19); 1 addressed tuberous sclerosis complex 2 (20); 3 were animal studies (21–23); 1 assessed amyloid precursor protein (4); 2 evaluated other biomarkers (24,25); 6 were exclusively in vitro studies (1;26–30); and 7 were reviews (2,31–36), thus leaving 21 studies. Examination of their full text led to the exclusion of 6 further studies since they did not report clinical studies (13,37–41). Overall, 15 studies met the inclusion criteria and are reviewed below.

Bottom Line: Most articles described in vivo studies using a morphological approach and immunohistochemistry, whereas protein expression was quantified as staining intensity scored by two raters.Often the results were not comparable due to the different rating scales and study design.Current research on HtrA1 does not conclusively support its role as a tumor suppressor.

View Article: PubMed Central - PubMed

Affiliation: Department of Life, Health and Environmental Sciences, Epidemiology and Biostatistics Unit, AUSL Teramo, University of L'Aquila, L'Aquila, Italy.

ABSTRACT
HtrA1 appears to be involved in several physiological processes as well as in the pathogenesis of conditions such as Alzheimer's disease and osteoarthritis. It has also been hypothesized to play a role as a tumor suppressor. This manuscript reviews the current cancer-related HtrA1 research from the methodological and clinical standpoints including studies regarding its potential role as a tumor marker and/or prognostic factor. PRISMA method was used for study selection. The articles thus collected were examined and selected by two independent reviewers; any disagreement was resolved by a methodologist. A laboratory researcher reviewed the methods and laboratory techniques. Fifteen studies met the inclusion criteria and concerned the following cancer sites: the nervous system, bladder, breast, esophagus, stomach, liver, endometrium, thyroid, ovaries, pleura, lung and skin. Most articles described in vivo studies using a morphological approach and immunohistochemistry, whereas protein expression was quantified as staining intensity scored by two raters. Often the results were not comparable due to the different rating scales and study design. Current research on HtrA1 does not conclusively support its role as a tumor suppressor.

No MeSH data available.


Related in: MedlinePlus